Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 35713772)

  • 1. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
    Frampton JE
    Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.
    Soo RA; de Marinis F; Han JY; Ho JC; Martin E; Servidio L; Sandelin M; Popat S
    Clin Lung Cancer; 2024 Jan; 25(1):80-84. PubMed ID: 37914594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
    Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
    J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
    Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
    BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib in Resected
    Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS;
    N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
    Herbst RS; Wu YL; John T; Grohe C; Majem M; Wang J; Kato T; Goldman JW; Laktionov K; Kim SW; Yu CJ; Vu HV; Lu S; Lee KY; Mukhametshina G; Akewanlop C; de Marinis F; Bonanno L; Domine M; Shepherd FA; Urban D; Huang X; Bolanos A; Stachowiak M; Tsuboi M
    J Clin Oncol; 2023 Apr; 41(10):1830-1840. PubMed ID: 36720083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
    Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
    Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
    Majem M; Goldman JW; John T; Grohe C; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Li S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Atagi S; Zeng L; Kulkarni D; Medic N; Tsuboi M; Herbst RS; Wu YL
    Clin Cancer Res; 2022 Jun; 28(11):2286-2296. PubMed ID: 35012927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
    Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.
    Lamb YN
    Target Oncol; 2021 Sep; 16(5):687-695. PubMed ID: 34564820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
    Zhao P; Zhen H; Zhao H; Zhao L; Cao B
    BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis.
    Wang J; Wu YL; Lu S; Wang Q; Li S; Zhong WZ; Wang Q; Li W; Wang B; Chen J; Cheng Y; Duan H; Li G; Shan L; Liu Y; Liu J; Huang X; Bolanos A; He J
    JTO Clin Res Rep; 2024 Feb; 5(2):100621. PubMed ID: 38371194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
    John T; Grohé C; Goldman JW; Shepherd FA; de Marinis F; Kato T; Wang Q; Su WC; Choi JH; Sriuranpong V; Melotti B; Fidler MJ; Chen J; Albayaty M; Stachowiak M; Taggart S; Wu YL; Tsuboi M; Herbst RS; Majem M
    J Thorac Oncol; 2023 Sep; 18(9):1209-1221. PubMed ID: 37236398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients.
    Maione P; Salvi R; Gridelli C
    Curr Oncol; 2024 Feb; 31(2):987-997. PubMed ID: 38392068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall Survival with Osimertinib in Resected
    Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; Su WC; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Poole L; Bolanos A; Rukazenkov Y; Wu YL;
    N Engl J Med; 2023 Jul; 389(2):137-147. PubMed ID: 37272535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA
    Zhang SS; Ou SI
    Lung Cancer (Auckl); 2022; 13():23-31. PubMed ID: 35506019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.
    Wu YL; Herbst RS; Mann H; Rukazenkov Y; Marotti M; Tsuboi M
    Clin Lung Cancer; 2018 Jul; 19(4):e533-e536. PubMed ID: 29789220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
    Passaro A; Mok TSK; Attili I; Wu YL; Tsuboi M; de Marinis F; Peters S
    JAMA Oncol; 2023 Aug; 9(8):1124-1131. PubMed ID: 37166792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the epidermal growth factor receptor following complete surgical resection in patients with early-stage non-small cell lung cancer.
    Shaverdashvili K; Burns TF
    Expert Opin Pharmacother; 2023; 24(11):1283-1293. PubMed ID: 37222405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.